KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension...(val of these two additional strengths wh...),Health

During fiscal 2007, ETHEX Corporation received three approvals from the FDA, including: Diltiazem HCL extended release capsules, Nystatin Topical Powder and a new formulation of Prednisolone Sodium Phosphate. The Company remains optimistic about the potential FDA approvals of important new Abbreviated New Drug Applications (ANDA's) from its robust internal pipeline as it moves through fiscal 2008, which are expected to benefit the overall performance of its generic/non-branded marketing business.

In addition to the large portfolio of products in its own internal development pipeline, the Company also continues to see progress on its products under its co-development agreements. The Company believes that co- development agreements will continue to add incremental revenues to ETHEX's revenue base from its existing products, resulting from new planned introductions during the remainder of fiscal 2008 and beyond.

Fiscal 2007 Business Highlights:

-- Concluded an agreement with Beijing Med-Pharm Corporation

for exclusive marketing and distribution rights to KV's proprietary

prescription, one-dose vaginal cream for bacterial vaginosis (BV),

Clindesse(R) (clindamycin phosphate vaginal cream 2%) in the People's

Republic of China;

-- Concluded an agreement with California-based VIVUS, Inc. for the

purchase of U.S. marketing rights to Evamist(TM), a novel estrogen

transdermal spray that has been developed to deliver estradiol in a

convenient easy-to-use dosage form for the treatment of vasomotor

symptoms associated with menopause;

-- Minneapolis Federal District Court jury found in favor of ETHEX/KV on

all Lanham Act claims made against K
'/>"/>